Market Overview

Morgan Stanley Maintains on Allscripts Healthcare Solutions

Related MDRX
New Survey Gives J.P. Morgan Confidence To Go Overweight Athenahealth, Allscripts & Advisory Board
Cookeville Medical Center Selects Allscripts for Chronic Care Management (CCM) Program
3 Industry Groups Show Strength, Rise Through Ranks (Investor's Business Daily)

In a report published Wednesday, Morgan Stanley analyst Julie Murphy maintained an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), raising its price target to $20.00 from $17.00.

According to the report, following the previous Morgan Stanley note “What a Difference a Year Makes! Turnaround Thesis Validated” published this morning, analysts are updating model estimates and price target for MDRX.

“Our PT is based on a 2.7x EV/Sales multiple, the 2-yr avg FY1 multiple for MDRX pre-April 2012 (prior to the strategic alternatives upheaval seen that year) applied to our base case 2015 revenue est of $1,523M,” the report noted. “Our bull case valuation of $23 reflects a 2.9x EV/Sales multiple (3-yr avg multiple pre-April 2012) applied to our bull case 2015 revenue estimate of $1607M. Our bear case valuation of $14 is based on a 2.0x multiple (3-yr avg multiple) applied to our bear case 2015 revenue estimate of $1,471M.”

MDRX closed Tuesday at $15.52 with shares trading up at 2.51 percent.

Latest Ratings for MDRX

Nov 2015JP MorganAssumesOverweight
Nov 2015Deutsche BankMaintainsBuy
Nov 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Julie Murphy Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (MDRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters